Affinia Therapeutics appoints Rami Daoud as CB-SFO
US gene therapies developer Affinia Therapeutics has appointed Rami Daoud as chief business and financial officer.
Mr Daoud is an accomplished biopharmaceutical business executive who is passionate about bringing to market innovative therapeutics aimed at saving lives and improving the health and well-being of patients globally.
He has more than 25 years’ professional and senior leadership experience working at large pharmaceutical and biotech companies in both public and private sectors including Amarin Corporation, Auxilium Pharmaceuticals, Eli Lilly (NYSE: LLY), and Human Genome Sciences. Mr Daoud has deep expertise across various therapeutic areas and commercialization models, and a successful track record of deal making and leading strategic initiatives globally in the USA, Europe, Japan, China and other emerging markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze